Health Care [ 3/12 ] | Biotechnology [ 13/73 ]
NASDAQ | Common Stock
Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases.
The company's lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425.
It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease; and a series of bispecific antibodies targeting DR3 and other clinically validated targets.
In addition, the company is involved in the advancement of its lead TRIM7 inhibitors through preclinical development as future internal pipeline candidates in oncology.
Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 30, 25 | -0.27 Increased by +27.03% | -0.28 Increased by +4.42% |
| Feb 26, 25 | -0.37 Increased by +9.76% | -0.32 Decreased by -16.06% |
| Nov 7, 24 | -0.33 Increased by +49.23% | -0.42 Increased by +21.43% |
| Aug 1, 24 | -0.42 Increased by +16.00% | -0.41 Decreased by -2.44% |
| May 2, 24 | -0.37 Increased by +24.49% | -0.45 Increased by +17.78% |
| Feb 29, 24 | -0.41 Increased by +31.67% | -0.57 Increased by +28.07% |
| Nov 9, 23 | -0.65 Decreased by -12.07% | -0.52 Decreased by -25.00% |
| Aug 10, 23 | -0.50 Increased by +23.08% | -0.52 Increased by +3.85% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 14.49 M Increased by +1.20 K% | -13.70 M Increased by +25.95% | Decreased by -94.55% Increased by +94.30% |
| Dec 31, 24 | 0.00 Decreased by -100.00% | -18.68 M Decreased by -5.61% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 3.00 M Increased by +336.88% | -16.68 M Increased by +39.45% | Decreased by -556.39% Increased by +86.14% |
| Jun 30, 24 | 1.61 M Increased by +704.50% | -21.55 M Decreased by -0.97% | Decreased by -1.34 K% Increased by +87.45% |
| Mar 31, 24 | 1.11 M Increased by +1.86 K% | -18.50 M Increased by +10.71% | Decreased by -1.66 K% Increased by +95.44% |
| Dec 31, 23 | 714.00 K Increased by +83.08% | -17.69 M Increased by +27.94% | Decreased by -2.48 K% Increased by +60.64% |
| Sep 30, 23 | 686.00 K Increased by +223.58% | -27.54 M Decreased by -11.80% | Decreased by -4.01 K% Increased by +65.45% |
| Jun 30, 23 | 200.00 K Increased by +300.00% | -21.35 M Increased by +21.19% | Decreased by -10.67 K% Increased by +80.30% |